RIPK3 and neoplasm: As shown in Figure 2, although administration of the combination therapy induced necrosis measured by RIP3 immunostaining (21) (Supplemental Figure 2) in implanted TNBC and reduced tumor volume, the long-term survival of tumor-bearing mice treated with the combination of CBDCA and anti-PD-1 antibodies still remained suboptimal due to metastases to other organs, among which the major target organ was the lungs (metastasis patterns were illustrated in Supplemental Figure 3).